Figure 4B shows results from our CyTOF-based differential expression (pre vs. post-17-AAG treatment) analysis, revealing shifts in IRF4 and pSTAT3 as well as myeloma cell survival markers like CD138 and phosphoproteins like pRB. This evidence concerns the gene RB1 and plasma cell myeloma.